BiotechTube
Home/Regel Therapeutics/Jordane Dimidschstein, Ph.D.
JD

Jordane Dimidschstein, Ph.D.

President, COO & Board Member

Regel Therapeutics

Therapeutic Areas

NeurologyGenetic Disorders

Regel Therapeutics Pipeline

DrugIndicationPhase
RT101Dravet SyndromePreclinical
RT102SCN2A HaploinsufficiencyPreclinical

Leadership Team at Regel Therapeutics

SJ
Stephen J. Farr, Ph.D.
CEO & Chairman of the Board
KA
Kate Allaway, Ph.D.
VP of Research
View full Regel Therapeutics profile